News & Events

A Billion Dollar Drug Using a Virtual Business Model

Oct 13, 2017

Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient In the drug development world, coming up with a billion-dollar drug is almost like winning the lottery, except that there is a lot of hard work, false leads, and significant technical and financial risk. This article discusses the…

Read More

Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA

Sep 26, 2017

Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…

Read More

Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market

Sep 26, 2017

Tozaride has demonstrated clinical effectiveness in treating lung cancer SOMERVILLE, Mass.— September 6, 2017— Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights…

Read More

Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting

Sep 22, 2017

  Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO)…

Read More

Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study

Sep 22, 2017

Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…

Read More

Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling

Oct 20, 2015

Andarix’ R&D expands to include Notch Influencing Molecules   ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…

Read More

Andarix Selected to Present at Prominent Drug Development Conferences

Sep 10, 2015

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall.  Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…

Read More

Andarix Selected to Present at Orphan Drug Congress

Apr 21, 2015

ANDARIX Pharmaceuticals, a clinical stage company developing a targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 23, 2015. Conference location and agenda information are available at the World Orphan Drug Congress. Andarix’…

Read More

Andarix Pharmaceuticals’ Targeted Therapy Demonstrates Efficacy in Pancreatic Cancer

Dec 2, 2014

Tozaride Demonstrates Pancreatic Tumor Reduction in Animal Model ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts”…

Read More

Andarix Pharmaceuticals Selected to Present at International Drug Conference in Copenhagen

Sep 17, 2014

ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at www.orphandrugssummit.com. Mr. Adams will highlight recent results…

Read More